On Medical Treatments & Products Archives

Joint Comments to the Consumer Product Safety Commission on the Notice of Proposed Rulemaking: “Safety Standard for Infant Support Cushions”

March 18, 2024: NCHR was one of 6 Consumer Safety groups submitting joint comments to the Consumer Product Safety Commission (CPSC) for its Proposed Rule for Safety Standards for Infant Support Cushions

NCHR Comment on Classification of Certain Wound Dressings

NCHR supports the proposed FDA rule, which aims to reclassify wound dressings and liquid wound washes containing antimicrobials based on their level of antimicrobial resistance (AMR), with higher-risk products categorized as Class III. This change is crucial for mitigating the public health threat posed by AMR, ensuring the appropriate use of these medical devices, and ultimately improving patient outcomes.

Statement of Dr. Diana Zuckerman on Behalf of the National Center for Health Research FDA Advisory Committee Meeting on AMX0035 for ALS

September 7, 2022 Diana Zuckerman testified on behalf of NCHR at the FDA Advisory Committee hearing about the poor evidence foe Amylyx drug AMX0035 for the treatment of ALS, and how approving this drug would undermine other ALS clinical trials that are underway.

NCHR’s Comment on EPA’s Proposed Lead and Copper Rule Improvements (LCRI)

February 2024: In its public comment, NCHR supported EPA’s proposed lead and copper rule improvements (LCRI) and suggested strengthening safeguards such as lowering the action lead level to 5 ppb or less, more attention to schools, daycares, and afterschool facilities, better enforcement, and not replacing lead pipes with PVC or other dangerous pipes.

NCHR Comments on USPSTF Draft Recommendations on Interventions for Adolescents with a High Body Mass Index

January 16, 2024: NCHR strongly supports USPSTF’s draft recommendation on using behavioral interventions to manage unhealthy weight gain in adolescents over six years of age with a body mass index at the 95th percentile for their age and sex. More research is needed to clearly show the safety and efficacy of weight loss medications in this patient population.